Phase 2 Start~month

Phase 2 Start: A Phase 2, Open-Label Study of CTX-471 in Patients With NCAM Positive Tumors

Indication
Neuroendocrine Tumors; Neuroendocrine Carcinomas; Neuroendocrine Neoplasm

Other upcoming events for CMPX

Phase 3 ReadoutPhase 3 Topline: A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination With Paclitaxel Versus Paclitaxel
Phase 3 ReadoutPhase 3 Topline: A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination With Paclitaxel Versus Paclitaxel

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 2 Start: A Phase 2, Open-Label Study of CTX-471 in Patients With NCAM Positive Tumors — CMPX Phase 2 Start | BioSniper